BioDelivery Sciences Planning Two Emezine PK Studies To Satisfy FDA Concerns
This article was originally published in The Pink Sheet Daily
The company believes that the studies of the anti-emetic will take six to nine months to complete.
You may also be interested in...
FDA "not approvable" letter for Emezine is due to the pharmacokinetic profile of its oral buccal tablet formulation.
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Merger will create the leading generic injectable pharmaceutical company in the world.